Clinical Trial Update: Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT [Phase 4]

View source ↗

Summary

A Phase 4 study comparing lenvatinib plus transarterial chemoembolization (TACE) versus sorafenib plus TACE for hepatocellular carcinoma with portal vein tumor …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Portal Vein Tumor Thrombus

Drugs mentioned

• Lenvatinib (lenvatinib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Beijing Ditan Hospital | Conditions: Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus | Phase 4 | Status: UNKNOWN